Exhibit 99.2

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Unaudited Interim Condensed Consolidated Balance Sheets
As of April 30, 2025 and October 31, 2024

 

   April 30,
2025
   October 31,
2024
 
   (Unaudited)     
ASSETS        
Current Assets        
Cash and cash equivalents   1,351,285    547,498 
Accounts receivable, net   123,257    330,892 
Due from related parties   34    14,339 
Inventories   65,821    71,486 
Advances to suppliers   2,647    19,168 
Loans receivable from franchisees, net   996,605    745,992 
Other receivables and other current assets   3,044,981    1,114,871 
Total current assets   5,584,630    2,844,246 
Non-current Assets          
Property and equipment, net   88,967    103,960 
Intangible assets, net   6,980    7,621 
Operating lease right of use asset   91,198    70,739 
Other non-current assets   60,657    56,717 
Total non-current assets   247,802    239,037 
TOTAL ASSETS   5,832,432    3,083,283 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities          
Accounts payable   16,803    24,069 
Due to related parties   7,460     
Taxes payable   1,198,269    1,001,024 
Operating lease liabilities – current   28,402    17,573 
Contract liability   118,277    325,924 
Accruals and other payables   149,721    155,863 
Total current liabilities   1,518,932    1,524,453 
Non-current liabilities          
Operating lease liabilities – non-current   63,060    52,745 
Total non-current assets   63,060    52,745 
TOTAL LIABILITIES   1,581,992    1,577,198 
           
Commitments and contingencies   
    
 
           
Shareholders’ equity          
Ordinary shares (2,500,000,000 shares authorized, par value $0.00002, 29,374,403 shares issued and outstanding as of April 30, 2025 and 25,000,000 shares issued and outstanding as of October 31, 2024) *   587    500 
Additional paid in capital   23,751,471    1,161,211 
Statutory reserve   131,962    131,962 
Accumulated deficits   (19,564,205)   271,788 
Accumulated other comprehensive loss   (69,375)   (59,376)
Total Shareholders’ equity   4,250,440    1,506,085 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   5,832,432    3,083,283 

 

 

*Certain shares are related to the IPO (See Note 14).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Income
For the Six Months Ended April 30, 2025 and 2024

 

   Six Months
Ended
April 30,
2025
   Six Months
Ended
April 30,
2024
 
Revenues, net   1,239,197    852,928 
Cost of revenues   58,500    98,109 
Gross profit   1,180,697    754,819 
           
Operating expenses          
Selling and marketing expenses   229,775    157,733 
General and administrative expenses   20,632,549    452,098 
Research and development expenses   26,087    20,083 
Allowance for expected credit losses   7,883    32,537 
Total operating expenses   20,896,294    662,451 
Operating (expenses) income   (19,715,597)   92,368 
           
Non-operating income (expense) items:          
Other income   58,154    
 
Other expense   
    133 
Interest income   416    1,051 
Interest expense   20    
 
Total other income   58,550    918 
           
(Loss) Income before income tax   (19,657,048)   93,286 
           
Income tax expense   178,946    44,386 
           
Net (loss) income   (19,835,994)   48,900 
           
Earnings per share          
Ordinary shares – basic and diluted   (0.74)   0.002 
Weighted average shares outstanding used in calculating basic and diluted earnings per share:          
Ordinary shares – basic and diluted   26,887,202    25,000,000 

 

 

*Certain shares are related to the IPO (See Note 14 ).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficits)
For the Six Months Ended April 30, 2025 and 2024

 

   Ordinary Shares       Additional        Retained earning   Accumulated Other     
   Number of Shares   Amount   Subscription
Receivable
   Paid-in
Capital
   Statutory
Reserves
   (Accumulated Deficits)   Comprehensive Loss   Total Equity 
Balance at October 31, 2023   25,000,000    500    (500)   1,161,211    30,422    (105,233)   (73,927)   1,012,473 
Contribution in capital        
 
    500              
 
    
 
    500 
Net income       
    
    
    
    48,900    
    48,900 
Appropriation to statutory reserve       
    
    
         
 
    
    
 
Foreign currency translation adjustment       
    
    
    
    
    6,135    6,135 
 Balance at April30, 2024   25,000,000    500    
    1,161,211    30,422    (56,333)   (67,792)   1,068,008 
                                         
Balance at October 31, 2024   25,000,000    500    
    1,161,211    131,962    271,788    (59,376)   1,506,085 
Issuance of shares, net   1,374,403    27    
    2,640,320    
    
    
    2,640,347 
Share-based Compensation   3,000,000    60    
    19,949,940    
    
    
    19,950,000 
Net loss       
    
    
    
    (19,835,994)   
    (19,835,994)
Foreign currency translation adjustment       
    
    
    
    
    (9,999)   (9,999)
Balance at April 30, 2025   29,374,403    587    
    23,751,471    131,962    (19,564,205)   (69,375)   4,250,440 

 

 

*Certain shares are related to the IPO (See Note 14 ).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Unaudited Interim Condensed Consolidated Statements of Cash Flows
For the Six Months Ended April 30, 2024 and 2023
(Unaudited)

 

   Six Months Ended
April 30,
2025
   Six Months Ended
April 30,
2024
 
Cash flows from operating activities        
Net income   (19,835,994)   48,900 
Depreciation and amortization   15,508    11,329 
Allowance for credit losses   7,883    32,537 
Impairments and write-offs of assets   4,734    214 
Deferred tax benefits   (1,993)   (6,793)
Operating lease expenses   14,098    11,652 
Share-based Compensation Expense   19,950,000    
 
Non-cash interest income   (29,000)    
 
Changes in operating assets and liabilities:          
Accounts receivable   201,410    185,952 
Inventories   (570)   4,502 
Advances to suppliers   16,124    (3,277)
Other receivables and other current assets   9,499    220,382 
Operating advance payments to related parties   (263)   
 
Other non-current assets   (3,141)   (247,098)
Accruals and other payables   (100,169)   (27,435)
Accounts payable   (6,762)   (144,708)
Taxes payable   218,358    78,547 
Contract liability   (200,867)   (121,326)
Operating lease liabilities   (13,422)   (12,092)
Net cash provided by operating activities   245,433    31,286 
Cash flows from investing activities          
Purchase of equipment and intangible assets   (2,213)   (2,071)
Loans to franchisees   (691,377)   (498,230)
Loan repayment from franchisees   416,890    322,630 
Loans to the third party   (3,000,000)     
Repayment from related parties   14,270    
 
Net cash used in investing activities   (3,262,430)   (177,671)
           
Cash flows from financing activities          
Proceeds from shareholder’s contribution of capital   
    500.00 
Proceeds from issuance of shares   4,277,807    
 
Borrowing from related party   7,462    36,501 
IPO Costs   (451,758)   
 
Net cash provided by financing activities   3,833,511    37,001 
           
Net increase (decrease) of cash and cash equivalents   816,514    (109,384)
           
Effect of foreign currency translation   (12,727)   7,716 
Cash and cash equivalents– beginning of period   547,498    1,033,634 
Cash and cash equivalents– end of period  $1,351,285   $931,966 
           
Supplementary cash flow information:          
Interest paid  $
   $
 
Income tax paid  $
   $
 
Non-cash investing and financing activities:          
Non-cash IPO Costs   (97,302)   
 
Non-cash interest income   29,000    
 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities  $34,759   $
 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial.

 

F-4

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 1 — ORGANIZATION AND BASIS OF PRESENTATION

 

Park Ha Biological Technology Co., Ltd. (“Park Ha Cayman”) was incorporated in the Cayman Islands on October 11, 2022. The Company is an investment holding company; its primary business operations are conducted through its subsidiaries as described below.

 

Park Ha Biological Technology (HK) Co., Ltd. (“Park Ha HK”) was incorporated in Hong Kong on October 25, 2022. It is a wholly owned subsidiary of Park Ha Cayman.

 

Park Ha Investment (Wuxi) Co., Ltd. (“Park Ha WFOE”) was incorporated on May 5, 2023 as a wholly foreign owned entity in the People’s Republic of China (“PRC”). Park Ha WFOE is a wholly owned subsidiary of Park Ha HK.

 

Wuxi Xinzhan Enterprise Management Consulting Co., Ltd. (“XinZhan”) was incorporated on March 31, 2016 in the People’s Republic of China (“PRC”) with Ms. Xiaoqiu Zhang being the majority shareholder owning 75.2% of XinZhan prior to the equity transfer described below. XinZhan takes the lead in promoting the franchisee market and looking for franchisees. XinZhan signs a franchise agreement with the franchisee. The franchise agreement grants the franchisee the license to open stores under the “PARK HA” brand in a specific area. Franchisees authorized to sell Park Ha Jiangsu’s “PARK HA” brand products or third-party products authorized by XinZhan must comply with the terms of the franchise agreement.

 

Shanghai Park Ha Industrial Development Co., Ltd. (“Park Ha Shanghai”) was incorporated on April 17, 2017 in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of Wuxi XinZhan. Park Ha Shanghai’s primary business includes beauty services, sales of beauty products and devices, management of beauty salon franchises.

 

Jiangsu Park Ha Biotechnology Co., Ltd. (“Park Ha Jiangsu”) was incorporated on August 13, 2019 in the People’s Republic of China (“PRC”) with Ms. Xiaoqiu Zhang being the majority shareholder owning 75.2% of Park Ha Jiangsu prior to the equity transfer described below. Park Ha Jiangsu has developed a full range of “PARK HA” brand skin care products through cooperation with biological laboratories. Our product range ranges from basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance and anti-aging. These products are sold through directly operated retail stores and franchisees.

 

On May 17, 2023, Park Ha WFOE entered into equity transfer agreements with each shareholder of Wuxi XinZhan and Park Ha Jiangsu to purchase all the equity interest in such entities. The restructure was completed on July 7, 2023. As a result, Wuxi XinZhan and Park Ha Jiangsu became a wholly owned subsidiary of Park Ha WFOE.

 

Wuxi Mufeng Biotechnology Co., Ltd (“Wuxi Mufeng”) and Wuxi Muchen Biotechnology Co., Ltd were incorporated on February 21, 2025 in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of Park Ha Jiangsu.

 

Huishan Yiyayue Beauty Salon (“Huishan Yiyayue”) was incorporated on January 22, 2025 in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of Park Ha Jiangsu.

 

Upon the completion of the above Reorganization, Park Ha Cayman became the ultimate holding company of all other entities mentioned above. The Company is effectively controlled by the same group of controlling shareholders before and after the Reorganization; therefore, the Reorganization is considered as a recapitalization of these entities under common control. The consolidation of the Company was accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying unaudited condensed consolidated financial statements. Results of operations for the period presented comprise those of the previous separate entries combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.

 

Park Ha Biological Technology Co., Ltd. and its subsidiaries are collectively referred to as the “Company”.

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the Company’s unaudited condensed consolidated financial statement. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the year ended October 31, 2024 included in the other.

 

F-5

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All inter-company balances and transactions are eliminated upon consolidation. Operating results for the six months ended April 30, 2025 and 2024 are not necessarily indicative of the results that may be expected for the full year.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, the valuation of the amount due from related parties, inventory valuations, the estimation of useful lives of property and equipment and intangible assets, allowance for expected credit losses, and income taxes including the valuation allowance for deferred tax assets. Actual results could differ from those estimates.

 

Functional and Presentation Currency

 

The functional currency of the Company is the currency of the primary economic environment in which the Company operates which is Chinese Yuan (“RMB”). The RMB is not freely convertible into the US dollar and may be subject to PRC currency restrictions for payments, including the distributions of dividends or retained earnings to the Company by its subsidiaries.

 

Transactions in currencies other than the entity’s functional currency are recorded at the rates of exchange prevailing on the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at the end of the reporting periods. Exchange differences arising on the settlement of monetary items and on translation of monetary items at period-end are included in income statement of the period.

 

For the purpose of presenting these financial statements, the Company’s assets and liabilities are expressed in US$ at the exchange rate on the balance sheet date, shareholder’s equity accounts are translated at historical rates, and income and expense items are translated at the periodic average exchange rate during the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) in the shareholder’s equity section of the balance sheets.

 

Exchange rate used for the translation as follows:

 

   As of 
   April 30,
2025
   October 31,
2024
 
Period end US$: RMB exchange rate   7.2706    7.1178 

 

   For the six months ended 
   April 30 
   2025   2024 
Period average US$: RMB exchange rate   7.2681    7.1754 

 

 

F-6

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Fair Values of Financial Instruments

 

The Company adopted ASC 820 “Fair Value Measurements,” which defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosures requirements for fair value measures. Current assets and current liabilities qualified as financial instruments and management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and if applicable, their current interest rate is equivalent to interest rates currently available. The three levels are defined as follow:

 

Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 — inputs to the valuation methodology are unobservable and significant to the fair value.

 

As of the balance sheet date, the estimated fair values of the financial instruments approximated their fair values due to the short-term nature of these instruments. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates the hierarchy disclosures each year.

 

Cash and Cash Equivalents

 

Cash consists of cash on hand and cash in bank, as well as balances in Douyin and Meituan accounts, which are highly liquid and have original maturities of three months or less and are unrestricted as to withdrawal or use. The Company maintains cash with various financial institutions primarily in mainland China. The Company has not experienced any losses in bank accounts. The balances in Douyin and Meituan represent transaction balances from customers purchasing products through these platforms. Merchants’ income can be withdrawn within 1-3 business days without any restrictions.

 

Accounts Receivable and allowance for credit losses

 

Accounts receivables are stated at the historical carrying amount net of allowance for expected credit losses.

 

The Company adopted ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” on January 1, 2023 using a modified retrospective approach. The Company also adopted this guidance to due from related parties, loans receivable from franchisees, other receivables. To estimate expected credit losses, the Company has identified the relevant risk characteristics of its customers and the related receivables. The Company considers the past collection experience, current economic conditions, future economic conditions (external data and macroeconomic factors) and changes in the Company’s customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

 

Inventory

 

Inventories, which are primarily comprised of finished goods for sale, goods shipped to customer and raw materials, are stated at the lower of cost or net realizable value, using the weighted average method and is based on purchase cost. The Company evaluates the need for reserves associated with obsolete, slow-moving and non-salable inventory by reviewing net realizable values on a periodic basis..

 

Loans Receivable

 

Loans receivable is recorded at origination at the fair value less estimates for expected credit losses. Loans receivable is reviewed periodically to determine whether it’’s carrying value has become impaired. The Company uses credit loss method to estimate the allowance for loans receivables.

 

Property and Equipment

 

Property and equipment are stated at historical cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Property and equipment are depreciated on a straight-line basis over the following periods:

 

Office furniture   5 years
Motor Vehicle   4 years
Office equipment   2.5-5 years
Leasehold improvements   Shorter of the remaining lease terms or estimated useful lives

 

F-7

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Intangible assets

 

Intangible assets with definite useful lives are amortized over their estimated useful lives to their estimated residual values. Intangible assets mainly represent software at cost, less accumulated amortization on a straight-line basis over an estimated life of ten years.

 

Impairment of long-lived assets other than goodwill

 

Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. Impairment charge recognized for the six months ended April 30, 2025 and 2024 was nil.

 

Related parties

 

The Company adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. According to the standard, financial statements are required to disclose material related-party transactions other than compensation arrangements, expense allowances, or other similar items that occur in the ordinary course of business. A related party is essentially any party that controls or can significantly influence the management or operating policies of the company to the extent that the company may be prevented from fully pursuing its own interests. Related parties include affiliates, investees accounted for by the equity method, trusts for the benefit of employees, principal owners, management, and immediate family members of owners or management. Transactions with related parties must be disclosed even if there is no accounting recognition made for such transactions (e.g., a service is performed without payment).

 

Lease

 

The Company recognizes right-of-use (“ROU”) assets and lease liabilities for its lease commitments with terms greater than one year. Contractual options to extend or terminate lease agreements are reflected in the lease term when they are reasonably certain to be exercised. The initial measurements of new ROU assets and lease liabilities are based on the present value of future lease payments over the lease term as of the commencement date. In determining future lease payments, the Company has elected not to separate lease and non-lease components. As the Company’s lease arrangements do not provide an implicit interest rate, we apply the Company’s incremental borrowing rate based on the information available at the commencement date in determining the present value of future lease payments. Relevant information used in determining the Company’s incremental borrowing rate includes the duration of the lease, transaction currency of the lease, and the Company’s credit risk relative to risk-free market rates. The Company’s ROU assets also include any initial direct costs incurred and exclude lease incentives. The Company’s lease agreements do not contain any significant residual value guarantees or restrictive covenants. All leases of the Company are classified as operating leases, with lease expense being recognized on a straight-line basis.

 

Revenue Recognition

 

In 2014, the FASB issued guidance on revenue recognition (“ASC 606”), with final amendments issued in 2016. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to its clients. The Company has concluded that the new guidance did not require any significant change to its revenue recognition processes.

 

F-8

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

The Company generate revenues from sales of beauty products and devices, and management of beauty salon franchises.

 

Sales of Beauty Products and Devices:

 

The contracts for sales of beauty products and devices are established either through direct transactions or through formal agreements, creating enforceable rights and obligations for both parties. For these sales, the Company recognizes a single performance obligation: the transfer of goods to the customer. There are no additional identifiable promises within these contracts. The Company does not offer price protection but do allow for the return of goods in cases of quality issues, adhering to the standard warranty practices. The Company recorded reserve for sales returns was $nil for the six months ended April 30, 2025, and 2024.

 

For sales at our owned store locations, revenue is recognized at the point of transfer of control, typically when the customer makes payment and accepts the goods in-store.

 

Regarding online sales via third-party platforms, control is transferred, and revenue is recognized at the point of delivery to the customer, facilitated by express delivery services.

 

Sales and deliveries of beauty products and devices to the franchisees are treated as distinct performance obligations, separate from the franchise agreement. These transactions are not highly dependent on, nor are they integrated with, the franchise services, allowing the franchisee to benefit from the goods independently. Revenue from sales to franchisees is recognized upon the transfer of control of the goods, generally upon delivery. As franchisees take ownership and resell the products at their discretion, these transactions are not considered consignment sales.

 

Management of beauty salon franchises:

 

The Company’s franchise revenues comprise non-refundable initial franchise fees received from franchisees. The initial franchise services, which constitute the Company’s obligation under these agreements, include: (i) granting exclusive operating rights in a specific area, (ii) allowing the use of the “PARK HA” brand, and (iii) providing initial setup services. These setup services encompass assistance with site selection, marketing strategy formulation, and training for franchisee management and beauticians.

 

Following the revenue recognition standard ASC 606, we consider the initial franchise services indistinct from the ongoing rights provided during the franchise agreement term. Consequently, these services are treated as a single performance obligation. Accordingly, initial franchise fees are deferred and recorded as a “Contract Liability.” These fees are recognized over the franchise term as the performance obligation is satisfied, typically spanning one year.

 

The Company offers advertising and renovation subsidies to franchisees, calculated as a percentage of the franchise fee. Since these subsidies are not in exchange for distinct goods or services from franchisees, they are accounted for as a reduction in the transaction price of the franchise fee.

 

The Company also offers short-term loans to franchisees, with terms not exceeding six months. The loan amounts are based on the franchise fee and a fixed ratio. Given the short duration of these loans, as a practical expedient, the Company does not adjust the consideration for the effects of a significant financing component.

 

Contract liability

 

The contract liabilities consist of advances from customers, which relate to unsatisfied performance obligations at the end of each reporting period and consists of cash payments received in advance from customers in sales of beauty products and devices and unearned franchise fee. As of April 30, 2025 and October 31, 2024, the Company’s advances from customer deposit and unearned franchise fee amounted to $118,277 and $325,924, respectively.

 

F-9

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

The Company reports revenues net of applicable sales taxes and related surcharges.

 

Cost of revenues

 

Costs of sales of beauty products and devices consist primarily of materials costs, shipping and handling expenses, inspection costs and related costs, which are directly attributable to products. Write-down of inventories is also recorded in cost of sales, if any.

 

Costs of revenue of beauty salon franchises consist primarily of training costs, promotional material costs and related costs, which are directly attributable to franchises business.

 

Shipping and handling fees incurred to transport goods to customers are paid directly to the logistics company by customers.

 

Selling and marketing expense

 

Sales and marketing expenses consist primarily of rent, depreciation of leasehold improvements, marketing conference expenses, advertising expenses and salaries and other compensation-related expenses to sales and marketing personnel. The Company expenses all advertising costs as incurred. Advertising costs were $3,010 and $nil for the six months ended April 30, 2025 and 2024, respectively.

 

General and administrative expenses

 

General and administrative expenses consist primarily of Share-based Compensation Expense、salaries and benefits for employees involved in general corporate functions and those not specifically dedicated to research and development activities, depreciation and amortization of fixed assets which are not used in research and development activities, legal and other professional services fees, rental and other general corporate related expenses.

 

Research and development

 

The Company expenses research and development expenses when incurred as periodic costs. The Company recognized research and development expenses for the six months ended April 30, 2025 and 2024 in the amounts of $26,087 and $20,083, respectively. Research and development expenses primarily comprise of employees’ wages and benefits, as well as expenditures related to patent fees.

 

Value Added Tax (VAT)

 

In accordance with the relevant tax laws in the PRC, VAT is levied on the invoiced value of sales and is payable by the purchaser. The Company is required to remit the VAT it collects to the tax authority but may deduct the VAT it has paid on eligible purchases. The difference between the amounts collected and paid is presented as VAT recoverable or payable balance on the balance sheet.

 

Income Taxes

 

Income taxes are provided in accordance with ASC No. 740, Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry-forwards. Deferred tax expense (benefit) results from the net change during the periods of deferred tax assets and liabilities.

 

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

F-10

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

A tax benefit from an uncertain tax position may be recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities. The determination is based on the technical merits of the position and presumes that the relevant taxing authority that has full knowledge of all relevant information will examine each uncertain tax position. Although the Company believes the estimates are reasonable, no assurance can be given that the final outcome of these matters will not be different than what is reflected in the historical income tax provisions and accruals.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) consists of two components, net income and other comprehensive income. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in foreign currency translation loss in the unaudited condensed consolidated statements of operations and comprehensive income.

 

Statutory Reserves

 

Pursuant to the laws applicable to the PRC, PRC entities must make appropriations from after-tax profit to the non-distributable “statutory surplus reserve fund”. Subject to certain cumulative limits, the “statutory surplus reserve fund” requires annual appropriations of 10% of after-tax profit until the aggregated appropriations reach 50% of the registered capital (as determined under accounting principles generally accepted in the PRC (“PRC GAAP”) at each year-end). For foreign-invested enterprises and joint ventures in the PRC, annual appropriations should be made to the “reserve fund”. For foreign-invested enterprises, the annual appropriation for the “reserve fund” cannot be less than 10% of after-tax profits until the aggregated appropriations reach 50% of the registered capital (as determined under PRC GAAP at each year-end). If the Company has accumulated loss from prior periods, the Company is able to use the current period net income after tax to offset the accumulated loss.

 

Earnings (loss) per share

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is calculated by dividing net income (loss) attributable to the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the period. For the six months ended April 30, 2025 and 2024, the Company does not have any outstanding ordinary shares equivalents; therefore, a separate computation of diluted earnings (loss) per share is not presented.

 

Commitments and Contingencies

 

The Company follows ASC 450-20, “Loss Contingencies,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of April 30, 2025 and October 31, 2024.

 

Segment reporting

 

ASC 280, Segment Reporting, (“ASC 280”), establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers.

 

Based on the criteria established by ASC 280, our chief operating decision maker (“CODM”) has been identified as our Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the company. As a whole and hence, we have two business segments which comprised of products sales and franchise service. As our long-lived assets are substantially located in the PRC, no geographical segments are presented.

 

F-11

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Concentration and risks

 

a) Concentration of credit risk

 

Financial instruments that potentially subject the Company to concentration of credit risk are cash and cash equivalents, and accounts receivable arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions or trading platforms.

 

The Company conducts credit evaluations of customers, and generally does not require collateral or other security from its customers. The Company establishes an allowance for expected credit losses primarily based upon the factors surrounding the credit risk of specific customers.

 

b) Foreign currency exchange rate risk

 

The functional currency and the reporting currency of the Company are RMB and U.S. dollars, respectively. The Company’s exposure to foreign currency exchange rate risk primarily relates to cash, accounts receivable and accounts payable. Any significant fluctuation of RMB against U.S. dollars may materially and adversely affect the Company’s cash flows, revenues, earnings and financial positions.

 

Recent Accounting Pronouncements

 

In November 2023, the FASB issued Accounting Standards Update No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.

 

Other accounting standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on, or are unrelated to, its consolidated financial condition, results of operations, cash flows or disclosures.

 

NOTE 3 — ACCOUNTS RECEIVABLES, NET

 

As of April 30, 2025 and October 31, 2024, accounts receivables, net is comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Accounts receivables – Non franchisees   155,865    157,769 
Allowance for expected credit losses   (152,784)   (157,769)
Accounts receivables, net – Non-franchisees   3,081    
 

 

   April 30,
2025
   October 31,
2024
 
Accounts receivables – Franchisees   193,711    404,974 
Allowance for expected credit losses   (73,535)   (74,082)
Accounts receivables, net – Franchisees   120,176    330,892 

 

F-12

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 3 — ACCOUNTS RECEIVABLES, NET (cont.)

 

The following is a summary of the activity in the allowance for expected credit losses:

 

   April 30,
2025
   October 31,
2024
 
Balance at beginning of period – Non-franchisees   157,769    24,398 
(Reversal) Provision   (1,669)   132,787 
Effect of translation adjustment   (3,316)   584 
Balance at end of period – Non-franchisees   152,784    157,769 

 

   April 30,
2025
   October 31,
2024
 
Balance at beginning of period – Franchisees   74,082    66,106 
Provision   1,010    6,393 
Effect of translation adjustment   (1,557)   1,583 
Balance at end of period – Franchisees   73,535    74,082 

 

NOTE 4 — INVENTORY, NET

 

As of April 30, 2025 and October 31, 2024, inventory comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Raw materials   17,503    22,606 
Goods shipped to customer   
-
    1,914 
Finished goods   48,318    46,966 
Inventories, net   65,821    71,486 

 

Inventory write-down expense was $4,734 and $214 for the six months ended April 30, 2025 and 2024, respectively.

 

NOTE 5 — LOANS RECEIVABLE FROM FRANCHISEES, NET

 

Loans receivables from franchisees consist of non-interest-bearing advances provided by the Company to its franchisees to purchase inventory, equipment; or for use as working capital. The maturity date of the loan is 180 days from the date of disbursement of funds.

 

As of April 30, 2025 and October 31, 2024, loan receivables from franchisees, net comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Loan receivables from franchisees   1,059,060    801,512 
Allowance for expected credit losses   (62,455)   (55,520)
Loan receivables from franchisees, net   996,605    745,992 

 

The following is a summary of the activity in the allowance for expected credit losses:

 

   April 30,
2025
   October 31,
2024
 
Balance at beginning of period   55,520    62,602 
Provision   8,101    (8,580)
Effect of translation adjustment   (1,166)   1,498 
Balance at end of period   62,455    55,520 

 

F-13

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 5 — LOANS RECEIVABLE FROM FRANCHISEES, NET (cont.)

 

The following is a summary of the movement of the loan:

 

   April 30,
2025
   October 31,
2024
 
Balance at beginning of period   801,512    362,917 
Loans lend to franchisees   691,377    1,236,518 
Repayment from franchisees   (416,890)   (810,660)
Effect of translation adjustment   (16,939)   12,737 
Balance at end of period   1,059,060    801,512 

 

The amount of loans that are past due as of April 30,2025 and October 31, 2024 were $430,501 and $55,495 respectively. As of the reporting date, the amount of loans that are past due is $378,923.

 

As of April 30, 2025 and October 31, 2024, loans receivable from franchisees, net comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Gao Wenjing   51,578    52,685 
Wang Shimei   51,578    
 
Xu Yong   8,940    
 
Nan Xifeng   8,940    
 
Zeng Yongjian   45,388    46,361 
Song Mingfang   51,578    
 
Wang Zhiya   
    52,685 
Yu Yang   51,578    52,685 
Wang Limin   
    52,685 
Zhou Guixiang   
    
 
Wang Jia   8,940    
 
Wang Xuefeng   178,802    182,641 
Wang Xiaohui   8,940    
 
Zheng Yanhai   8,940    9,132 
Chen Yu   
    9,132 
Zhang Ying   
    9,132 
Wang Hongli   
    9,132 
Ge Xiaoqing   
    9,132 
Zhu Hongjun   51,578    52,685 
Liu Jie   51,578    52,685 
Zhou Qianqian   51,578    52,685 
Meng Hao   
    52,685 
Liu Zonghui   
    52,685 
Li Ruonan   
    52,685 
Yan Tianxiang   8,940    
 
Wu Yinghan   178,802    
 
Liu Yuping   178,802    
 
Xiao Yang   17,880    
 
Sun Zhongyao   8,940    
 
Shen Yue   8,940    
 
Sun Xuqiang   8,940    
 
Zhao Zhe   8,940    
 
Fan Lingfu   8,940    
 
    1,059,060    801,512 
Less: Allowance for expected credit loss   (62,455)   (55,520)
Loan receivables from franchisees, net   996,605    745,992 

 

F-14

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 6 — OTHER RECEIVABLES AND OTHER CURRENT ASSETS, net

 

As of April 30, 2025 and October 31, 2024, other receivables and other current assets comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Other receivables   3,091,207    69,454 
Deferred IPO Cost   
    1,088,400 
Prepaid expenses   4,154    8,030 
Total   3,095,361    1,165,884 
Allowance for expected credit loss   (50,380)   (51,013)
Other receivables and other current assets, net   3,044,981    1,114,871 

 

The following is a summary of the activity in the allowance for expected credit losses:

 

   April 30,
2025
   October 31,
2024
 
Balance at beginning of period- Other receivables   51,013    
 
Provision   (633)   51,013 
Effect of translation adjustment   
    
 
Balance at end of period other receivables   50,380    51,013 

 

NOTE 7 — PROPERTY & EQUIPMENT, NET

 

As of April 30, 2025 and October 31, 2024, property and equipment, net comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
At Cost:          
Office furniture   8,669    8,855 
Motor vehicle   144,471    147,573 
Office equipment   10,171    8,129 
Leasehold improvements   104,531    106,775 
Total, Cost   267,842    271,332 
Accumulated depreciation   (178,875)   (167,372)
Total, net   88,967    103,960 

 

Depreciation expenses were $15,026 and $10,841 for the six months ended April 30, 2025 and 2024, respectively.

 

NOTE 8 — INTANGIBLE ASSETS, NET

 

As of April 30, 2025 and October 31, 2024, intangible assets, net comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
At Cost:          
Trademark   248    253 
Software   9,628    9,834 
           
Accumulated depreciation   (2,896)   (2,466)
Total, net   6,980    7,621 

 

Amortization expenses were $482 and $488 for the six months ended April 30, 2025 and 2024, respectively.

 

   For the years ending October 31, 
    2025*    2026    2027    2028    2029    thereafter 
Amortization expenses   481    963    963    963    963    2,647 

 

 

*        For the six months ending October 31, 2025

 

F-15

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 9 — OTHER NON-CURRENT ASSETS

 

As of April 30, 2025 and October 31, 2024, other non-current assets comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Lease deposits   3,539    407 
Deferred Tax Asset   57,118    56,310 
Total   60,657    56,717 

 

NOTE 10 — TAXES PAYABLE

 

As of April 30, 2025 and October 31, 2024, taxes payable comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Enterprise income tax payable   865,632    699,633 
Value-added tax, net   299,215    271,404 
City maintenance and construction tax   19,025    17,018 
Additional education fees   8,295    7,438 
Other taxes   6,102    5,531 
Total   1,198,269    1,001,024 

 

NOTE 11 — CONTRACT LIABILITIES

 

For service contracts where the performance obligation is not completed, contract liabilities were recorded for any payments received in advance of the performance obligation. The payments received in advance will not be refunded and will be amortized in future when met performance obligations.

 

As of April 30, 2025 and October 31, 2024, contract liabilities is comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Unearned franchise fee   118,277    309,315 
Customer advance for beauty products   
    16,609 
Total   118,277    325,924 

 

The unearned franchise fee of $118,277 is to be recognized to revenue within one year from April 30, 2025.

 

F-16

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 11 — CONTRACT LIABILITIES (cont.)

 

As of April 30, 2025 and October 31, 2024, unearned franchise fee comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Li Yi   38    7,005 
Gao Wenjing   
    31,563 
Yan Tianxiang   1,507    
 
Wu Yinghan   32,753    
 
Liu Yuping   36,462    
 
Wang Shimei   2,073    
 
Xu Yong   754    
 
Nan Xifeng   829    
 
Song Mingfang   6,971    
 
Wang Zhiya   
    23,287 
Yu Yang   
    
 
Wang Limin   
    12,510 
Li Jie   
    6,390 
Sheng Xidong   
    6,890 
Zhou Guixiang   
    13,626 
Wang Jia   415    
 
Wang Xuefeng   528    40,801 
Wang Xiaohui   641    
 
Ge Xiaoqing   
    6,967 
Li Ruonan   
    2,309 
Meng Hao   
    7,313 
Chen Yu   
    500 
Wang Hongli   
    2,848 
Zhang Ying   
    2,964 
Liu Zonghui   
    16,359 
Xiao Yang   1,507    
 
Sun Zhongyao   1,055    
 
Shen Yue   1,206    
 
Fan Lingfu   1,130    
 
Sun Xuqiang   1,130    
 
Zhao Zhe   1,130    
 
Zheng Tinghai   5,162    
 
Liu Jie   6,971    41,955 
Zhu Hongjun   10,551    45,612 
Zhou Qianqian   5,464    40,416 
Total   118,277    309,315 

 

F-17

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 12 — RELATED PARTY TRANSACTIONS

 

The Company had transactions with the following related parties:

 

Name of Related Party   Nature of Relationship
Guozhen Liu   Limited partner of Changxin International Limited Partnership, executive director and legal representative of Park Ha Shanghai, supervisor of XinZhan, parent of Xiaoqiu Zhang
Fujun Yu   Executive director, legal representative of Park Ha Jiangsu, supervisor of Park Ha Shanghai
Hengquan Zhang   Supervisor of Park Ha Jiangsu, parent of Xiaoqiu Zhang
Xiaoqiu Zhang   CEO, Chairperson of the board of directors, controlling shareholder of Park Ha Cayman

 

Due from related party

 

The Company made advances to Ms. Xiaoqiu Zhang for working capital to be paid on behalf of the Company. The balance due from Ms. Xiaoqiu Zhang was $nil and $14,339 as of April 30, 2025 and October 31, 2024, respectively.

 

The Company made advances to Mr. Hengquan Zhang for working capital to be paid on behalf of the Company. The balance due from Mr. Hengquan Zhang was $34 and $nil as of April 30, 2025 and October 31, 2024, respectively.

 

Due to related party

 

The Company received advances from Ms. Xiaoqiu Zhang as working capital. The balance due to Ms. Xiaoqiu Zhang was $7,460 and $nil as of April 30, 2025 and October 31, 2024, respectively.

 

The amounts due from related party and due to related party above are non-interest bearing, without maturity and due on demand.

 

F-18

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 13 — LEASES

 

As of April 30, 2025, the Company has operating leases for seven operating leases for its two office locations, three company-operated stores, one staff dormitory and one warehouse. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease term.

 

Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is incremental borrowing rate or, if available, the rate implicit in the lease.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

 

   For the Six Months End 
   April 30, 
   2025   2024 
Lease Cost          
Operating lease cost  $14,098   $11,652 
           
Other Information          
Cash paid for amounts included in the measurement of lease liabilities  $13,422   $12,092 

 

As of April 30, 2025 and October 31, 2024, the weighted average lease term and discount rate are as follows:

 

   April 30,
2025
   October 31,
2024
 
Weighted average remaining lease term – operating leases (in years)   4.08    4.64 
Average discount rate – operating lease   3.77%   3.75%

 

As of April 30, 2025 and October 31, 2024, the supplemental balance sheet information related to leases are as follows:

 

   April 30,
2025
   October 31,
2024
 
Operating leases          
Right-of-use assets  $91,198   $70,739 
           
Operating lease liabilities, current  $28,402   $17,573 
Operating lease liabilities, non-current   63,060   $52,745 
Total operating lease liabilities  $91,462   $70,318 

 

F-19

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 13 — LEASES (cont.)

 

The undiscounted future minimum lease payment schedule as follows:

 

For the years ending April 30,    
Remainder of 2025   16,403 
2026   28,552 
2027   26,199 
2028   14,635 
2029   11,598 
Total undiscounted lease payments   97,387 
Less imputed interest   (5,925)
Total lease liabilities   91,462 

 

NOTE 14 — SHAREHOLDERS’ EQUITY

 

The Company was incorporated in the Cayman Islands in October 2022 under the Cayman Islands Companies Act as an exempted company with limited liability. As of April 30, 2025, the Company is authorized to issue 2,500,000,000 ordinary shares.

 

As of April 30, 2025, the Company has 29,374,403 shares issued and outstanding with a par value of $0.00002 per share.

 

On December 30, 2024, the Company completed initial public offering, issued and sold 1,200,000 Ordinary Shares, of which 1,200,000 shares related to the public offering, at $4.00 per share for $4.80 million. The net proceeds of $3.89 million after deducting underwriting discounts and the offering expenses payable was received by the Company.

 

On January 24, 2025, the Company issued and sold 174,403 shares to an over-allotment arrangement, at $4.00 per share for $0.70 million. The net proceeds of 0.38million after deducting underwriting discounts and the offering expenses payable was received by the Company

 

On February 28, 2025, the Board of Directors resolved and approved: the company adopt the 2025 Equity Incentive Plan, under which the total number of authorized and issuable shares of the company’s common stock (with a par value of $0.00002 per share) shall be 3,000,000 shares. On March 5, 2025, the company entered into five grant agreements with the respective grantees, specifying the grant date as March 5, 2025, with the vesting arrangement being immediately exercisable. The company recognized share-based compensation included in administrative expenses of $ 19,950,000 for the six months ended April 30, 2025, calculated based on the fair value price of $ 6.65 per share on the grant date of March 5,2025 multiplied by 3,000,000 shares.

 

F-20

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 15 — RESTRICTED NET ASSETS

 

As a result of the PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. Amounts restricted include paid-in capital, additional paid-in capital, and the statutory reserves of the Company’s PRC subsidiaries.

 

   As of 
   April 30,
2025
   October 31,
2024
 
Paid-in capital   
    
 
Additional paid in capital   1,161,211    1,161,211 
Statutory reserve   131,962    131,962 
Total   1,293,173    1,293,173 

 

NOTE 16 — SEGMENTS AND GEOGRAPHIC INFORMATION

 

The Company believes that it operates in two business segments which comprised of products sales and franchise service; and it operates in one geographical location China. The Company disaggregates its revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

Summarized financial information for the two reportable segments is as follows:

 

   Six Months Ended April 30, 2025 
   Product Sales   Franchise fees   Consolidated 
Revenues, net   404,438    834,759    1,239,197 
Cost of revenues   47,882    10,618    58,500 
Gross profit   356,556    824,141    1,180,697 
Depreciation and amortization   15,508         15,508 
Other expense (income), net   7,112,270    13,709,967    20,822,237 
Income tax expenses (benefits)   1,262    177,684    178,946 
Net (Loss) Income   (6,772,484)   (13,063,510)   (19,835,994)

 

   Six Months Ended April 30, 2024 
   Product Sales   Franchise fees   Consolidated 
Revenues, net   300,958    551,970    852,928 
Cost of revenues   40,224    57,885    98,109 
Gross profit   260,734    494,085    754,819 
Depreciation and amortization   7,274    4,055    11,329 
Other expense (income), net   415,785    234,419    650,204 
Income tax expenses (benefits)   (5,366)   49,752    44,386 
Net (Loss) Income   (156,959)   205,859    48,900 

 

Summarized financial information for revenues, costs and profits is as follows

 

Sales revenues comprised of the following:

   Six Months Ended 
   April 30,
2025
   April 30,
2024
 
Products sales – Non-franchisees   208,701    17%   164,958    19%
Product Sales – Franchisees   195,737    16%   136,000    16%
Franchise fees   834,759    67%   551,970    65%
Total   1,239,197    100%   852,928    100%

 

F-21

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 16 — SEGMENTS AND GEOGRAPHIC INFORMATION (cont.)

 

Direct costs comprised of the following:

 

   Six Months Ended 
   April 30,
2025
   April 30,
2024
 
Products sales – Non-franchisees   10,316    18%   11,764    12%
Product Sales – Franchisees   37,566    64%   28,460    29%
Franchise fees   10,618    18%   57,885    59%
Total   58,500    100%   98,109    100%

 

Gross profit comprised of the following:

 

   Six Months Ended 
   April 30,
2025
   April 30,
2024
 
Products sales – Non-franchisees   198,385    17%   153,194    20%
Product Sales – Franchisees   158,171    13%   107,540    15%
Franchise fees   824,141    70%   494,085    65%
Total   1,180,697    100%   754,819    100%

 

NOTE 17 — CONCENTRATION RISKS

 

Concentration of credit risk

 

Cash deposits with banks are held in financial institutions in China, which deposits are not federally insured. Accordingly, the Company has a concentration of credit risk related to the uninsured part of bank deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk.

 

Concentration of customers and suppliers

 

The Company has a concentration risk related to suppliers and customers. Failure to maintain existing relationships with the suppliers or customers to establish new relationships in the future could negatively affect the Company’s ability to obtain goods sold to customers in a price advantage and timely manner. If the Company is unable to obtain ample supply of goods from existing suppliers or alternative sources of supply, the Company may be unable to satisfy the orders from its customers, which could materially and adversely affect revenues.

 

The customers accounting for 10% or more of the Company’s revenue include the following:

 

   For the Six Months Ended 
   April 30,
2025
   April 30,
2024
 
Percentage of Company revenue        
Customer F   9%   15%
Customer G   9%   14%

 

The customers that accounted for 10% or more of the Company’s accounts receivable comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Percentage of the Company’s accounts receivable          
Customer A   26%   17%
Customer B   10%   7%
Customer C   
%   1%
Customer D   5%   3%
Customer E   
%   8%
Customer F   
%   15%
Customer G   
%   14%
Customer H   13%   8%
Customer I   13%   9%

 

F-22

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 17 — CONCENTRATION RISKS (cont.)

 

The suppliers that accounted for 10% or more of the Company’s purchases comprised of the following:

 

   For the Six Months Ended 
   April 30,
2025
   April 30,
2024
 
Percentage of the Company’s purchases        
Supplier A   12%   19%
Supplier B   12%   16%
Supplier C   13%   12%
Supplier D   
%   10%
Supplier E   14%   
%
Supplier H   11%   4%
Supplier I   11%   6%

 

The suppliers that accounted for 10% or more of the Company’s account payables comprised of the following:

 

   April 30,
2025
   October 31,
2024
 
Percentage of the Company’s accounts payable          
Supplier F   
%   36%
Supplier G   77%   55%
Supplier J   13%   9%

 

NOTE 18 — INCOME TAX

 

Cayman Islands

 

Under the current laws of the Cayman Islands, entities are not subject to tax on income or capital gain. In addition, payments of dividends by the Company to their shareholders are not subject to withholding tax in the Cayman Islands.

 

Hong Kong

 

Park Ha Biological Technology (HK) Co., Ltd. is incorporated in Hong Kong and is subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate for the first HKD$2 million of assessable profits is 8.25% and assessable profits above HKD$2 million will continue to be subject to the rate of 16.5% for corporations in Hong Kong, effective from the year of assessment 2018/2019. Park Ha Biological Technology (HK) Co., Ltd. did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Under Hong Kong tax laws, Park Ha Biological Technology (HK) Co., Ltd.is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends for the six months ended April 30, 2025 and April 30, 2024.

 

F-23

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 18 — INCOME TAX (cont.) 

 

China, PRC

 

The Company in general is subject to profits tax rate at 25% for income generated for its operation in China and net operating losses can be carried forward for no longer than five years starting from the year subsequent to the year in which the loss was incurred.

 

In accordance with the implementation rules of EIT Laws, a qualified “High and New Technology Enterprise” (“HNTE”) is eligible for a preferential tax rate of 15%. The HNTE certificate is effective for a period of three years. An entity could re-apply for the HNTE certificate when the prior certificate expires. “Park Ha Jiangsu” obtained its HNTE certificate on November 6, 2024. Therefore, “Park Ha Jiangsu” is eligible to enjoy a preferential tax rate of 15% from 2024 to 2026 to the extent it has taxable income under the EIT Law..

 

Announcement No. 12 [2023] of the Ministry of Finance and the State Taxation Administration stipulates that the preferential corporate income tax (CIT) policy for small and low-profit enterprises (SLPEs) — reducing taxable income by 25% and applying a 20% tax rate — shall be extended until December 31, 2027.Wuxi Muchen and Wuxi Mufeng , with annual taxable income not exceeding RMB 1 million for the six months ended April 30, 2025, qualify as SLPEs. As such, 25% of their taxable income is subject to CIT at the reduced rate of 20%.

 

Announcement No. 12 [2023] of the Ministry of Finance and the State Taxation Administration on Further Tax and Fee Support Policies for Micro and Small Enterprises and Individual Businesses From January 1, 2023, to December 31, 2027, 50% of the personal income tax (PIT) payable on the portion of an individual business’s annual taxable income not exceeding RMB 2 million shall be exempted. Individual businesses may enjoy this preferential policy cumulatively with other existing PIT incentives. Huishan Yiyayue , as an individual business with taxable income not exceeding RMB 1 million for the six months ended April 30, 2025, is eligible for a 50% reduction in PIT on its business income, which is subject to the five-tier progressive tax rates.

 

Income taxes in the PRC are consist of:

 

   For the Six Months Ended 
   April 30, 
   2025   2024 
Current income tax expense   180,939    51,179 
Deferred income tax benefit   (1,993)   (6,793)
Total income tax expense   178,946    44,386 

 

F-24

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 18 — INCOME TAX (cont.)

 

The net taxable income before income taxes and its provision for income taxes comprised of the following:

   For the Six Months Ended 
   April 30, 
   2025   2024 
(Loss) Income attributed to China   (19,657,048)   93,286 
PRC statutory tax rate   25%   25%
Income tax expense at PRC statutory income tax rate   (4,914,262)   23,322 
Tax effect of preferential tax treatments   5,059,645    2,706 
Research and development credit   (3,913)   (3,013)
Non-deductible expenses   1,862    13,472 
Change in valuation allowance   35,614    7,899 
Tax expense, net   178,946    44,386 

 

As of April 30, 2025and October 31, 2024, deferred tax assets consist of the following:

 

   As of 
   April 30,
2025
   October 31,
2024
 
Net operating losses carried forward in the PRC   119,211    85,404 
Allowance of expected credit loss   57,118    56,310 
Total   176,329    141,714 
Less: Valuation allowance   (119,211)   (85,404)
Deferred tax assets, net   57,118    56,310 

 

As of April 30, 2025 and October 31, 2024, the Company’s PRC entities had net operating loss carryforwards of approximately $0.67 million and $0.47 million, respectively which will start to expire from 2025. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will not be fully realized. As of April 30, 2025 and October 31, 2024, full valuation allowance is provided against the deferred tax assets related to the Company’s net operating loss carryforwards based upon management’s assessment as to their realization.

 

NOTE 19 — SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the filing of the financial statements and determined that there have been no events that have occurred that would require adjustments to or disclosure in the consolidated financial statements except for the following:

 

On March 3, 2025, Astra Nova Ventures Limited borrowed US$ 3 million from the Company under a loan agreement with a term from March 3, 2025 to October 15, 2025. The parties subsequently agreed on July 28, 2025 to terminate the original agreement early as of July 30, 2025. As of this reporting date, the company has fully recovered the loan in advance.

 

On July 7, 2025, the company’s board of directors approved the adoption of the Amended Plan, which amended and restated the company’s 2025 Share Incentive Plan. An additional 4,500,000 ordinary shares of US$0.00002 each of the Company (the “Shares’”) be and are reserved from the authorized unissued share capital of the Company for issuance under the Amended Plan such that the aggregate number of Shares authorized and deliverable under the Amended Plan was 7,500,000. The Company executed four Share Award Agreements on July 14, 2025, with four consultant grantees, conferring an aggregate of 4,500,000 shares with immediate vesting arrangement as of the Grant Date (July 14, 2025)

 

NOTE 20 — PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION

 

Park Ha Biological Technology Co., Ltd. (“Park Ha Cayman”) was incorporated in the Cayman Islands on October 11, 2022.

 

The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X, as the restricted net assets of the subsidiaries of Park Ha Cayman exceed 25% of the consolidated net assets of the Company. For purposes of the test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party (i.e., lender, regulatory agency, foreign government, etc.). The ability of the Company’s Chinese operating subsidiaries to pay dividends may be restricted due to the foreign exchange control policies and availability of cash balances of the Chinese operating subsidiaries. Because substantially all of the Company’s operations are conducted in China and a substantial majority of the Company’s revenues are generated in China, a majority of the Company’s revenue being earned and currency received are denominated in Renminbi (“RMB”). RMB is subject to the exchange control regulation in China, and, as a result, the Company may be unable to distribute any dividends outside of China due to PRC exchange control regulations that restrict the Company’s ability to convert RMB into US Dollars. 

 

F-25

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries
Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 20 — PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION (cont.)

 

The condensed parent company financial statements have been prepared using the same accounting principles and policies described in the notes to the unaudited condensed consolidated financial statements, with the only exception being that the parent company accounts for its subsidiaries using the equity method. Refer to the unaudited condensed consolidated financial statements and notes presented above for additional information and disclosures with respect to these financial statements.

 

As of April 30, 2025 and October 31, 2024, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stock or guarantees of the Company, except for those that have been separately disclosed in the consolidated financial statements, if any.

 

Condensed Balance Sheets

 

   April 30,   October 31, 
   2025   2024 
ASSETS        
Current Assets          
Cash and cash equivalents   1,015,018    
 
Other receivables and other current assets   3,029,000    
 
Deferred IPO Cost        1,088,400 
Total Current Assets   4,044,018    1,088,400 
Non-Current Assets          
Investment in subsidiaries   2,217,273    1,879,477 
Total Non-Current Assets   2,217,273    1,879,477 
TOTAL ASSETS   6,261,291    2,967,877 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities          
Intercompany Payable   2,010,851    1,461,792 
Total Current Liabilities   2,010,851    1,461,792 
TOTAL LIABILITIES   2,010,851    1,461,792 
Shareholders’ Equity          
Ordinary shares (2,500,000,000 shares authorized, par value $0.00002, 29,374,403 shares issued and outstanding as of April 30,2025 and 25,000,000 shares issued and outstanding as of October 31, 2024)*   587    500 
Additional Paid In Capital   23,751,471    1,161,211 
Statutory Reserve   131,962    131,962 
Retained Earnings (Accumulated Deficits)   (19,564,205)   271,788 
Accumulated Other Comprehensive Loss   (69,375)   (59,376)
Total Stockholders’ Equity   4,250,440    1,506,085 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   6,261,291    2,967,877 

 

 

*Certain shares are related to the IPO (See Note 14 ).

 

Condensed Statements of Operations

 

   Six Months
Ended
April 30,
2025
   Six Months
Ended
April 30,
2024
 
Operating costs and expenses:          
General and administrative expenses   20,212,966    
 
Total operating expenses   20,212,966    
 
Other income (expense):         
Other income   29,001    
 
Interest income   196    
 
Interest expense   20    
 
Total other income (expenses)   29,178    
 
Share of income of subsidiaries   347,794    48,900 
Net (loss) income   (19,835,994)   48,900 

 

F-26

 

http://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember P10Y http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 380000 0001986247 false 2025-04-30 Q2 --10-31 0001986247 2024-11-01 2025-04-30 0001986247 2025-04-30 0001986247 2024-10-31 0001986247 us-gaap:RelatedPartyMember 2025-04-30 0001986247 us-gaap:RelatedPartyMember 2024-10-31 0001986247 2023-11-01 2024-04-30 0001986247 us-gaap:CommonStockMember 2023-10-31 0001986247 phh:SubscriptionReceivableMember 2023-10-31 0001986247 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001986247 phh:StatutoryReserveMember 2023-10-31 0001986247 us-gaap:RetainedEarningsMember 2023-10-31 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-31 0001986247 2023-10-31 0001986247 us-gaap:CommonStockMember 2023-11-01 2024-04-30 0001986247 phh:SubscriptionReceivableMember 2023-11-01 2024-04-30 0001986247 us-gaap:RetainedEarningsMember 2023-11-01 2024-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-11-01 2024-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-04-30 0001986247 phh:StatutoryReserveMember 2023-11-01 2024-04-30 0001986247 us-gaap:CommonStockMember 2024-04-30 0001986247 phh:SubscriptionReceivableMember 2024-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001986247 phh:StatutoryReserveMember 2024-04-30 0001986247 us-gaap:RetainedEarningsMember 2024-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0001986247 2024-04-30 0001986247 us-gaap:CommonStockMember 2024-10-31 0001986247 phh:SubscriptionReceivableMember 2024-10-31 0001986247 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001986247 phh:StatutoryReserveMember 2024-10-31 0001986247 us-gaap:RetainedEarningsMember 2024-10-31 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-31 0001986247 us-gaap:CommonStockMember 2024-11-01 2025-04-30 0001986247 phh:SubscriptionReceivableMember 2024-11-01 2025-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-04-30 0001986247 phh:StatutoryReserveMember 2024-11-01 2025-04-30 0001986247 us-gaap:RetainedEarningsMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-11-01 2025-04-30 0001986247 us-gaap:CommonStockMember 2025-04-30 0001986247 phh:SubscriptionReceivableMember 2025-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001986247 phh:StatutoryReserveMember 2025-04-30 0001986247 us-gaap:RetainedEarningsMember 2025-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0001986247 phh:XinZhanMember 2016-03-31 0001986247 phh:ParkHaJiangsuMember 2019-08-13 0001986247 phh:PeoplesRepublicOfChinaMember 2024-11-01 2025-04-30 0001986247 phh:PeriodEndMember 2025-04-30 0001986247 phh:PeriodEndMember 2024-10-31 0001986247 phh:AverageMember 2025-04-30 0001986247 phh:AverageMember 2024-04-30 0001986247 phh:OfficeFurnitureMember 2025-04-30 0001986247 us-gaap:VehiclesMember 2025-04-30 0001986247 srt:MaximumMember us-gaap:OfficeEquipmentMember 2025-04-30 0001986247 srt:MinimumMember us-gaap:OfficeEquipmentMember 2025-04-30 0001986247 us-gaap:LeaseholdImprovementsMember 2025-04-30 0001986247 phh:NonFranchiseesMember 2025-04-30 0001986247 phh:NonFranchiseesMember 2024-10-31 0001986247 phh:FranchiseesMember 2025-04-30 0001986247 phh:FranchiseesMember 2024-10-31 0001986247 phh:NonFranchiseesMember 2023-10-31 0001986247 phh:NonFranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:NonFranchiseesMember 2023-11-01 2024-10-31 0001986247 phh:FranchiseesMember 2023-10-31 0001986247 phh:FranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:FranchiseesMember 2023-11-01 2024-10-31 0001986247 us-gaap:FranchiseMember us-gaap:FinancialAssetPastDueMember 2025-04-30 0001986247 us-gaap:FranchiseMember us-gaap:FinancialAssetPastDueMember 2024-10-31 0001986247 us-gaap:FranchiseMember 2025-04-30 0001986247 us-gaap:LoansReceivableMember 2024-11-01 2025-04-30 0001986247 phh:GaoWenjingMember 2025-04-30 0001986247 phh:GaoWenjingMember 2024-10-31 0001986247 phh:WangShimeiMember 2025-04-30 0001986247 phh:WangShimeiMember 2024-10-31 0001986247 phh:XuYongMember 2025-04-30 0001986247 phh:XuYongMember 2024-10-31 0001986247 phh:NanXifengMember 2025-04-30 0001986247 phh:NanXifengMember 2024-10-31 0001986247 phh:ZengYongjianMember 2025-04-30 0001986247 phh:ZengYongjianMember 2024-10-31 0001986247 phh:SongMingfangMember 2025-04-30 0001986247 phh:SongMingfangMember 2024-10-31 0001986247 phh:WangZhiyaMember 2025-04-30 0001986247 phh:WangZhiyaMember 2024-10-31 0001986247 phh:YuYangMember 2025-04-30 0001986247 phh:YuYangMember 2024-10-31 0001986247 phh:WangLiminMember 2025-04-30 0001986247 phh:WangLiminMember 2024-10-31 0001986247 phh:ZhouGuixiangMember 2025-04-30 0001986247 phh:ZhouGuixiangMember 2024-10-31 0001986247 phh:WangJiaMember 2025-04-30 0001986247 phh:WangJiaMember 2024-10-31 0001986247 phh:WangXuefengMember 2025-04-30 0001986247 phh:WangXuefengMember 2024-10-31 0001986247 phh:WangXiaohuiMember 2025-04-30 0001986247 phh:WangXiaohuiMember 2024-10-31 0001986247 phh:ZhengYanhaiMember 2025-04-30 0001986247 phh:ZhengYanhaiMember 2024-10-31 0001986247 phh:ChenYuMember 2025-04-30 0001986247 phh:ChenYuMember 2024-10-31 0001986247 phh:ZhangYingMember 2025-04-30 0001986247 phh:ZhangYingMember 2024-10-31 0001986247 phh:WangHongliMember 2025-04-30 0001986247 phh:WangHongliMember 2024-10-31 0001986247 phh:GeXiaoqingMember 2025-04-30 0001986247 phh:GeXiaoqingMember 2024-10-31 0001986247 phh:ZhuHongjunMember 2025-04-30 0001986247 phh:ZhuHongjunMember 2024-10-31 0001986247 phh:LiuJieMember 2025-04-30 0001986247 phh:LiuJieMember 2024-10-31 0001986247 phh:ZhouQianqianMember 2025-04-30 0001986247 phh:ZhouQianqianMember 2024-10-31 0001986247 phh:MengHaoMember 2025-04-30 0001986247 phh:MengHaoMember 2024-10-31 0001986247 phh:LiuZonghuiMember 2025-04-30 0001986247 phh:LiuZonghuiMember 2024-10-31 0001986247 phh:LiRuonanMember 2025-04-30 0001986247 phh:LiRuonanMember 2024-10-31 0001986247 phh:YanTianxiangMember 2025-04-30 0001986247 phh:YanTianxiangMember 2024-10-31 0001986247 phh:WuYinghanMember 2025-04-30 0001986247 phh:WuYinghanMember 2024-10-31 0001986247 phh:LiuYupingMember 2025-04-30 0001986247 phh:LiuYupingMember 2024-10-31 0001986247 phh:XiaoYangMember 2025-04-30 0001986247 phh:XiaoYangMember 2024-10-31 0001986247 phh:SunZhongyaoMember 2025-04-30 0001986247 phh:SunZhongyaoMember 2024-10-31 0001986247 phh:ShenYueMember 2025-04-30 0001986247 phh:ShenYueMember 2024-10-31 0001986247 phh:SunXuqiangMember 2025-04-30 0001986247 phh:SunXuqiangMember 2024-10-31 0001986247 phh:ZhaoZheMember 2025-04-30 0001986247 phh:ZhaoZheMember 2024-10-31 0001986247 phh:FanLingfuMember 2025-04-30 0001986247 phh:FanLingfuMember 2024-10-31 0001986247 2024-05-01 2024-10-31 0001986247 us-gaap:FranchiseMember 2024-10-31 0001986247 us-gaap:FranchiseMember 2023-10-31 0001986247 us-gaap:FranchiseMember 2024-11-01 2025-04-30 0001986247 us-gaap:FranchiseMember 2023-11-01 2024-10-31 0001986247 us-gaap:FurnitureAndFixturesMember 2025-04-30 0001986247 us-gaap:FurnitureAndFixturesMember 2024-10-31 0001986247 us-gaap:VehiclesMember 2024-10-31 0001986247 us-gaap:OfficeEquipmentMember 2025-04-30 0001986247 us-gaap:OfficeEquipmentMember 2024-10-31 0001986247 us-gaap:LeaseholdImprovementsMember 2024-10-31 0001986247 us-gaap:TrademarksMember 2025-04-30 0001986247 us-gaap:TrademarksMember 2024-10-31 0001986247 phh:SoftwareMember 2025-04-30 0001986247 phh:SoftwareMember 2024-10-31 0001986247 phh:LiYiMember 2025-04-30 0001986247 phh:LiYiMember 2024-10-31 0001986247 phh:GaoWenjingMember 2025-04-30 0001986247 phh:GaoWenjingMember 2024-10-31 0001986247 phh:YanTianxiangMember 2025-04-30 0001986247 phh:YanTianxiangMember 2024-10-31 0001986247 phh:WuYinghanMember 2025-04-30 0001986247 phh:WuYinghanMember 2024-10-31 0001986247 phh:LiuYupingMember 2025-04-30 0001986247 phh:LiuYupingMember 2024-10-31 0001986247 phh:WangShimeiMember 2025-04-30 0001986247 phh:WangShimeiMember 2024-10-31 0001986247 phh:XuYongMember 2025-04-30 0001986247 phh:XuYongMember 2024-10-31 0001986247 phh:NanXifengMember 2025-04-30 0001986247 phh:NanXifengMember 2024-10-31 0001986247 phh:SongMingfangMember 2025-04-30 0001986247 phh:SongMingfangMember 2024-10-31 0001986247 phh:WangZhiyaMember 2025-04-30 0001986247 phh:WangZhiyaMember 2024-10-31 0001986247 phh:YuYangMember 2025-04-30 0001986247 phh:YuYangMember 2024-10-31 0001986247 phh:WangLiminMember 2025-04-30 0001986247 phh:WangLiminMember 2024-10-31 0001986247 phh:LiJieMember 2025-04-30 0001986247 phh:LiJieMember 2024-10-31 0001986247 phh:ShengXidongMember 2025-04-30 0001986247 phh:ShengXidongMember 2024-10-31 0001986247 phh:ZhouGuixiangMember 2025-04-30 0001986247 phh:ZhouGuixiangMember 2024-10-31 0001986247 phh:WangJiaMember 2025-04-30 0001986247 phh:WangJiaMember 2024-10-31 0001986247 phh:WangXuefengMember 2025-04-30 0001986247 phh:WangXuefengMember 2024-10-31 0001986247 phh:WangXiaohuiMember 2025-04-30 0001986247 phh:WangXiaohuiMember 2024-10-31 0001986247 phh:GeXiaoqingMember 2025-04-30 0001986247 phh:GeXiaoqingMember 2024-10-31 0001986247 phh:LiRuonanMember 2025-04-30 0001986247 phh:LiRuonanMember 2024-10-31 0001986247 phh:MengHaoMember 2025-04-30 0001986247 phh:MengHaoMember 2024-10-31 0001986247 phh:ChenYuMember 2025-04-30 0001986247 phh:ChenYuMember 2024-10-31 0001986247 phh:WangHongliMember 2025-04-30 0001986247 phh:WangHongliMember 2024-10-31 0001986247 phh:ZhangYingMember 2025-04-30 0001986247 phh:ZhangYingMember 2024-10-31 0001986247 phh:LiuZonghuiMember 2025-04-30 0001986247 phh:LiuZonghuiMember 2024-10-31 0001986247 phh:XiaoYangMember 2025-04-30 0001986247 phh:XiaoYangMember 2024-10-31 0001986247 phh:SunZhongyaoMember 2025-04-30 0001986247 phh:SunZhongyaoMember 2024-10-31 0001986247 phh:ShenYueMember 2025-04-30 0001986247 phh:ShenYueMember 2024-10-31 0001986247 phh:FanLingfuMember 2025-04-30 0001986247 phh:FanLingfuMember 2024-10-31 0001986247 phh:SunXuqiangMember 2025-04-30 0001986247 phh:SunXuqiangMember 2024-10-31 0001986247 phh:ZhaoZheMember 2025-04-30 0001986247 phh:ZhaoZheMember 2024-10-31 0001986247 phh:ZhengTinghaiMember 2025-04-30 0001986247 phh:ZhengTinghaiMember 2024-10-31 0001986247 phh:LiuJieMember 2025-04-30 0001986247 phh:LiuJieMember 2024-10-31 0001986247 phh:ZhuHongjunMember 2025-04-30 0001986247 phh:ZhuHongjunMember 2024-10-31 0001986247 phh:ZhouQianqianMember 2025-04-30 0001986247 phh:ZhouQianqianMember 2024-10-31 0001986247 phh:MrHengquanZhangMember 2025-04-30 0001986247 phh:MrHengquanZhangMember 2024-10-31 0001986247 phh:MrFujunYuMember 2025-04-30 0001986247 phh:MrFujunYuMember 2024-10-31 0001986247 phh:GuozhenLiuMember 2024-11-01 2025-04-30 0001986247 phh:FujunYuMember 2024-11-01 2025-04-30 0001986247 phh:HengquanZhangMember 2024-11-01 2025-04-30 0001986247 phh:XiaoqiuZhangMember 2024-11-01 2025-04-30 0001986247 us-gaap:IPOMember 2024-12-30 0001986247 us-gaap:IPOMember 2024-12-30 0001986247 2024-12-30 0001986247 2024-12-30 2024-12-30 0001986247 2025-01-24 0001986247 2025-01-24 2025-01-24 0001986247 us-gaap:CommonStockMember 2025-02-28 0001986247 us-gaap:CommonStockMember 2025-02-28 2025-02-28 0001986247 2025-03-05 2025-03-05 0001986247 srt:ReportableGeographicalComponentsMember phh:ProductSalesMember 2024-11-01 2025-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:FranchiseFeesMember 2024-11-01 2025-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ConsolidatedMember 2024-11-01 2025-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ProductSalesMember 2023-11-01 2024-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:FranchiseFeesMember 2023-11-01 2024-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ConsolidatedMember 2023-11-01 2024-04-30 0001986247 phh:ProductsSalesNonfranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:ProductsSalesNonfranchiseesMember 2023-11-01 2024-04-30 0001986247 phh:ProductSalesFranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:ProductSalesFranchiseesMember 2023-11-01 2024-04-30 0001986247 phh:FranchiseFeesMember 2024-11-01 2025-04-30 0001986247 phh:FranchiseFeesMember 2023-11-01 2024-04-30 0001986247 phh:CustomerFMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerFMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-04-30 0001986247 phh:CustomerGMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerGMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-04-30 0001986247 phh:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerFMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerFMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerHMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerHMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 phh:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-11-01 2025-04-30 0001986247 phh:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-11-01 2024-10-31 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierAMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierAMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierBMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierBMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierCMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierCMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierDMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierDMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierHMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierHMember 2023-11-01 2024-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierIMember 2024-11-01 2025-04-30 0001986247 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember phh:SupplierIMember 2023-11-01 2024-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierFMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierFMember 2023-11-01 2024-10-31 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierGMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierGMember 2023-11-01 2024-10-31 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2023-11-01 2024-10-31 0001986247 country:HK 2024-11-01 2025-04-30 0001986247 phh:ParkHaBiologicalTechnologyMember 2024-11-01 2025-04-30 0001986247 phh:ChinaPRCMember phh:HighAndNewTechnologyEnterpriseMember 2025-04-30 0001986247 phh:HighAndNewTechnologyEnterpriseMember 2024-11-01 2025-04-30 0001986247 phh:ParkHaJiangsuMember 2024-11-01 2025-04-30 0001986247 srt:MaximumMember 2024-11-01 2025-04-30 0001986247 srt:MinimumMember 2024-11-01 2025-04-30 0001986247 2025-03-03 0001986247 srt:ScenarioForecastMember 2025-07-07 2025-07-07 0001986247 srt:ScenarioForecastMember us-gaap:IPOMember 2025-07-07 2025-07-07 0001986247 srt:ScenarioForecastMember 2025-07-07 0001986247 srt:ScenarioForecastMember 2025-07-14 0001986247 srt:ParentCompanyMember 2025-04-30 0001986247 srt:ParentCompanyMember 2024-10-31 0001986247 srt:ParentCompanyMember 2024-11-01 2025-04-30 0001986247 srt:ParentCompanyMember 2023-11-01 2024-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:HKD iso4217:CNY